AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19906002 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol valerate 2 mg + testosterone undecanoate 40 mg (E/T)
Number of subjects: 50
Study 19906002 — intervention group
Group type: COMPARATOR
Intervention: estradiol valerate 2 mg + placebo (E/P)
Number of subjects: 50
Study 16764134 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua Meron
Number of subjects: 86
Study 16764134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 86
Study 15635515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/mL
Number of subjects: 32
Study 15635515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg/mL
Number of subjects: 32
Study 10905386 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training intervention lasting 5 weeks
Number of subjects: 38
Study 10905386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 8880037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ample choice of food items consisting of mainly one macronutrient each offered 4 and 6 times per day with varying macronutrient compositions
Number of subjects: 68
Study 1557008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 0
Study 1557008 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 0
Study 6396247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole
Number of subjects: 69
Study 6396247 — intervention group
Group type: COMPARATOR
Intervention: Miconazole
Number of subjects: 69
Study 6396247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tioconazole and miconazole
Number of subjects: 69
Study 30760332 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH vacuum pump
Number of subjects: 104
Study 30760332 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy consisting of Acticoat TM and Mepitel TM
Number of subjects: 104
Study 28978680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) provided to women during pregnancy and the first 6 months postpartum and/or to their children from 6 to 18-24 months
Number of subjects: 4669
Study 28978680 — intervention group
Group type: COMPARATOR
Intervention: Non-Lipid-based nutrient supplements (non-LNS)
Number of subjects: 4669
Study 26926660 — intervention group
Group type: EXPERIMENTAL
Intervention: externally-supported intervention
Number of subjects: 1767
Study 26926660 — intervention group
Group type: EXPERIMENTAL
Intervention: teacher-supported intervention
Number of subjects: 1767
Study 26926660 — intervention group
Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 1767
Study 24445391 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin concentration (PRC)
Number of subjects: 88
Study 24445391 — intervention group
Group type: COMPARATOR
Intervention: Plasma renin activity (PRA)
Number of subjects: 88
Study 24445391 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism patients
Number of subjects: 88
Study 22246216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates (n = 44)
Number of subjects: 87
Study 22246216 — intervention group
Group type: COMPARATOR
Intervention: General exercise (n = 43)
Number of subjects: 87
Study 22246216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates
Number of subjects: 87
Study 22246216 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 87
Study 21057560 — intervention group
Group type: EXPERIMENTAL
Intervention: RHAMM expression tested by RT-PCR in chronic phase CML patients (44 patients)
Number of subjects: 60
Study 21057560 — intervention group
Group type: EXPERIMENTAL
Intervention: RHAMM expression tested by RT-PCR in accelerated/blastic phase CML patients (16 patients)
Number of subjects: 60
Study 21057560 — intervention group
Group type: EXPERIMENTAL
Intervention: RHAMM positive patients in chronic phase CML
Number of subjects: 60
Study 21057560 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 60
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dose of 1 mg/m(2).d (group A)
Number of subjects: 73
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: GH dose of 2 mg/m(2).d (group B)
Number of subjects: 73
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 73
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline free IGF‐I and IGFBP‐3
Number of subjects: 73
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bone age delay, target height SDS, baseline height SDS, and GH dose
Number of subjects: 73
Study 17504895 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline free IGF‐I
Number of subjects: 73
Study 15354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.4 mg
Number of subjects: 0
Study 15354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 0
Study 15354005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg
Number of subjects: 0
Study 15354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 0
Study 11676153 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 11676153 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 11676153 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening s.c. GH injections (2 IU)
Number of subjects: 14
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning s.c. GH injections (2 IU)
Number of subjects: 14
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: No GH administration
Number of subjects: 14
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: Two boluses i.v. GH (at 2000 and 0200 h)
Number of subjects: 14
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight boluses i.v. GH (at 3 h intervals starting at 2000 h)
Number of subjects: 14
Study 9678531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of GH (2000-2000 h)
Number of subjects: 14
Study 9678531 — intervention group
Group type: COMPARATOR
Intervention: Healthy untreated subjects (control group)
Number of subjects: 14
Study 7734465 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity neurobehavioral therapy
Number of subjects: 62
Study 7734465 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity control therapy
Number of subjects: 62
Study 2817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) with unmodified Dp-extract
Number of subjects: 46
Study 2817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) with mPEG modified Dp-extract
Number of subjects: 46
Study 2817306 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ctls)
Number of subjects: 46
Study 2817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) groups
Number of subjects: 46
Study 2817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with improved pulmonary symptoms
Number of subjects: 46
Study 5565516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 272
Study 5565516 — intervention group
Group type: COMPARATOR
Intervention: I.U.D.
Number of subjects: 272
Study 5565516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (stopped or changed)
Number of subjects: 272
Study 5565516 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (remained on the same)
Number of subjects: 272
Study 31625599 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical likelihood estimate
Number of subjects: 0
Study 31625599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lagrange multiplier (LM) test
Number of subjects: 0
Study 29999201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (1.25 × 10^8 bacteria/day)
Number of subjects: 134
Study 29999201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 29197913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 34
Study 29197913 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's anatomic knowledge (Control)
Number of subjects: 34
Study 29197913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography (performed by a single surgeon)
Number of subjects: 34
Study 25286317 — intervention group
Group type: EXPERIMENTAL
Intervention: Different piece of fruit selected in the afternoon after a morning selection of fruit (Study 1)
Number of subjects: 375
Study 25286317 — intervention group
Group type: EXPERIMENTAL
Intervention: Different piece of fruit selected in the afternoon after a morning selection of fruit (Study 2)
Number of subjects: 375
Study 22738315 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated sodium butyrate (MSB)
Number of subjects: 66
Study 22738315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0
Study 21810307 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 0
Study 21810307 — intervention group
Group type: COMPARATOR
Intervention: Benzimidazoles
Number of subjects: 0
Study 19387704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and methylprednisolone
Number of subjects: 150
Study 19387704 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 150
Study 16751034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed shunt
Number of subjects: 118
Study 16751034 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt shunt
Number of subjects: 118
Study 14628495 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/24 h DHEA
Number of subjects: 12
Study 14628495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11140558 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+gel (subgingival scaling plus 25% metronidazole gel)
Number of subjects: 88
Study 11140558 — intervention group
Group type: COMPARATOR
Intervention: SRP (subgingival scaling)
Number of subjects: 88
Study 11140558 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+gel
Number of subjects: 88
Study 11140558 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 88
Study 9167457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg twice a day)
Number of subjects: 603
Study 9167457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 1345409 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 47
Study 1345409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3897082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg t.i.d.
Number of subjects: 3
Study 3897082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg t.i.d.
Number of subjects: 3
Study 3897082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 29895502 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated Suvaxyn® CSF Marker vaccine (CP7_E2alf), administered intramuscularly on day 44 of gestation.
Number of subjects: 8
Study 29895502 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group (2 sows).
Number of subjects: 8
Study 27722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training (8 sessions)
Number of subjects: 14
Study 27722837 — intervention group
Group type: COMPARATOR
Intervention: Combat-exposed veterans without PTSD (n=12)
Number of subjects: 14
Study 24388126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention consisting of two motivational interviewing-guided group sessions led by a pharmacist
Number of subjects: 123
Study 24388126 — intervention group
Group type: COMPARATOR
Intervention: Control group received brochures about their DMARDs
Number of subjects: 123
Study 23579894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocured ultrathin flowable composite lining (0.5‐1mm) with overlying composite (Group II)
Number of subjects: 50
Study 23579894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocured thin lining (1‐1.5mm) with overlying composite (Group III)
Number of subjects: 50
Study 23579894 — intervention group
Group type: COMPARATOR
Intervention: P60 filling alone (Group I)
Number of subjects: 50
Study 23579894 — intervention group
Group type: EXPERIMENTAL
Intervention: Precuring ultrathin lining (0.5‐1 mm) (Group IV)
Number of subjects: 50
Study 23579894 — intervention group
Group type: EXPERIMENTAL
Intervention: Precuring thin lining (1‐1.5) (Group V)
Number of subjects: 50
Study 23579894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocured specimens (Groups II and III)
Number of subjects: 50
Study 19830558 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Streptococcus faecium) for 2 weeks with oral sodium phosphate (NaP)
Number of subjects: 211
Study 19830558 — intervention group
Group type: COMPARATOR
Intervention: Placebo with oral sodium phosphate (NaP)
Number of subjects: 211
Study 19830558 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Streptococcus faecium)
Number of subjects: 211
Study 19830558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 18504612 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronic acid 6 mg infused over 15 min every 28 days
Number of subjects: 0
Study 18504612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronic acid 50 mg/day
Number of subjects: 0
Study 16766588 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 667
Study 16766588 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 667
Study 16766588 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 32 mg
Number of subjects: 667
Study 16766588 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg with dexamethasone
Number of subjects: 667
Study 12869893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 13-15 mg/kg/d
Number of subjects: 180
Study 12869893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 12201317 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation of SSR antidepressants
Number of subjects: 0
Study 7745318 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser haemorrhoidectomy
Number of subjects: 0
Study 7745318 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 0
Study 2345592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and sodium restriction
Number of subjects: 16
Study 2345592 — intervention group
Group type: COMPARATOR
Intervention: Sodium restriction
Number of subjects: 16
Study 2345592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and hydrochlorothiazide
Number of subjects: 16
Study 2345592 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 16
Study 2345592 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and nifedipine
Number of subjects: 16
Study 2345592 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study 6780998 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 mg of inhaled cocaine
Number of subjects: 8
Study 6780998 — intervention group
Group type: COMPARATOR
Intervention: No cocaine (control)
Number of subjects: 8
Study 31599168 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counselling (4 weekly sessions)
Number of subjects: 80
Study 31599168 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study 31520480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with porous tantalum rod implantation and intra-arterial infusion of peripheral blood stem cells (PBSCs)
Number of subjects: 0
Study 31520480 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management (control group)
Number of subjects: 0
Study 31218866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic onlay
Number of subjects: 60
Study 31218866 — intervention group
Group type: COMPARATOR
Intervention: Resin composite
Number of subjects: 60
Study 28489182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise (cycle ergometer for lower limbs, 30 minutes, 60-70% of maximal heart rate)
Number of subjects: 30
Study 28489182 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 26790202 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep acupuncture (group A) at Lianquan (CV 23) with a depth of 60-70 mm
Number of subjects: 251
Study 26790202 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow acupuncture (group B) at Lianquan (CV 23) with a depth of 30-40 mm
Number of subjects: 251
Study 26790202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glossopharyngeum acupuncture (group C)
Number of subjects: 251
Study 23467073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Number of subjects: 18
Study 21299472 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 36
Study 21299472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19755916 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐TOH (750 IU/d)
Number of subjects: 12
Study 19755916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16790655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous small-dose morphine (4 mg/70 kg)
Number of subjects: 8
Study 16790655 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 15799917 — intervention group
Group type: EXPERIMENTAL
Intervention: Incor LVAD
Number of subjects: 13
Study 15799917 — intervention group
Group type: EXPERIMENTAL
Intervention: Excor LVAD
Number of subjects: 13
Study 11590633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention allocation k' or k'(s)
Number of subjects: 0
Study 11590633 — intervention group
Group type: EXPERIMENTAL
Intervention: Score test or skewness-corrected score test
Number of subjects: 0
Study 9734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LoDAC)
Number of subjects: 0
Study 9734695 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0
Study 9734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 0
Study 9734695 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 7917367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 122
Study 7917367 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 122
Study 2550700 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐HIGP (2 ml per kg body weight one time in four weeks)
Number of subjects: 85
Study 2550700 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐HIGP (1 ml per kilogram of body weight) every two to three weeks initially, with double dose for basic immunisation protection
Number of subjects: 85
Study 2550700 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 85
Study 8980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 383
Study 8980 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate with trisulfapyrimidines
Number of subjects: 383
Study 8980 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 383
Study 8980 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin estolate
Number of subjects: 383
Study 7240435 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine plus chlorpromazine
Number of subjects: 10
Study 7240435 — intervention group
Group type: COMPARATOR
Intervention: meperidine plus placebo
Number of subjects: 10
Study 31344403 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission TRPG measurement
Number of subjects: 469
Study 31344403 — intervention group
Group type: COMPARATOR
Intervention: Lower TRPG
Number of subjects: 469
Study 30019498 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg once daily for 24 weeks
Number of subjects: 613
Study 30019498 — intervention group
Group type: COMPARATOR
Intervention: dapagliflozin 5 mg titrated to 10 mg once daily for 24 weeks
Number of subjects: 613
Study 27163985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (different order for second reading)
Number of subjects: 1194147
Study 27163985 — intervention group
Group type: COMPARATOR
Intervention: Control group (same order for second reading)
Number of subjects: 1194147
Study 27163985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1194147
Study 27163985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1194147
Study 24988105 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to outdoor areas
Number of subjects: 6261
Study 24988105 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to workout facilities within a worksite
Number of subjects: 6261
Study 24988105 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a cafeteria and fewer vending machines
Number of subjects: 6261
Study 24988105 — intervention group
Group type: EXPERIMENTAL
Intervention: Better eating habits
Number of subjects: 6261
Study 24988105 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting physical activity recommendations
Number of subjects: 6261
Study 22253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated drug-free mini-tablets 2 mm in diameter
Number of subjects: 60
Study 22253279 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of glucose syrup 15%
Number of subjects: 60
Study 19952869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity training for parents in the NICU (10 sessions)
Number of subjects: 45
Study 19952869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sensitivity training)
Number of subjects: 45